Keywords
renal replacement therapy
hemodialysis
mineral bone disease
Cinacalcet Hydrochloride
How to Cite
Abstract
The effectiveness of the drug Cinacalcet Hydrochloride for the treatment of secondary hyperparathyroidism, and its effect on the state of phosphorus-calcium homeostasis was evaluated in patients receiving renal replacement therapy by hemodialysis. It was revealed that the prevalence of secondary hyperparathyroidism in patients on renal replacement therapy by hemodialysis was 66 %. The use of Cinacalcet for 6 months allowed to achieve a significant reduction in the serum level of parathyroid hormone in most patients, including those with severe hyperparathyroidism, and also contributed to the normalization of phosphorus-calcium metabolism. The effect of therapy with Cinacalcet on the secretion of parathyroid hormone depended on the prescribed dose and severity of hyperparathyroidism. The most effective was the treatment of patients with moderate hyperparathyroidism.
References
Ветчинникова О. Н. Гиперпаратиреоз при хронической болезни почек / О. Н. Ветчинникова // Эффективная фармакотерапия. Урология и нефрология. – 2013. – № 2. – С. 26–39.
Miller P. D. Bone disease in CKD: a focus on osteoporosis diagnosis and management / P. D. Miller // Am. J. Kidney Dis. – 2014. – Vol. 64. – P. 290–304.
Kenneth R. Phelps. Tradeoff-in-the-nephron: a theory to explain the primacy of phosphate in the pathogenesis of secondary hyperparathyroidism / Kenneth R. Phelps // Nutrients. – 2017. – Vol. 9 (5). – Pii 427.
The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism / P. Messa, F. Macário, M. Yaqoob [et al.] // Clin. J. Am. Soc. Nephrol. – 2008. – Vol. 3 (1). – P. 36–45.
Clinical outcomes in secondary hyperparathyroidism and the potential role of calcimimetics / J. Cunningham, J. Floege, G. London [et al.] // NDT Plus. 2008. – Vol. 1, suppl. 1. – i29–i35.
International burden of chronic kidney disease and secondary hyperparathyroidism: a systematic review of the literature and available data / E. Hedgeman, L. Lipworth, K. Lowe [et al.] // Int. J. Nephrol. – 2015. – Vol. 2015. – P. 184321.
Blayney M. J. Trends and consequences of mineral bone disorder in haemodialysis patients: lessons from the Dialysis Outcomes and Practice Patterns Study (DOPPS) / M. J. Blayney, F. Tentori // J. Ren. Care. – 2009. – Vol. 35, suppl. 1. – P. 7–13.
Cinacalcet use and the risk of cardiovascular events, fractures and mortality in chronic kidney disease patients with secondary hyperparathyroidism / M. Evans, S. Methven, A. Gasparini [et al.] // Sci. Rep. – 2018. – Vol. 8 (1). – P. 2103.
Management of secondary hyperparathyroidism: practice patterns and outcomes of cinacalcet treatment with or without active vitamin D in Austria and Switzerland – the observational TRANSIT Study / W. Pronai, A. R. Rosenkranz, A. Bock [et al.] // Wien Klin. Wochenschr. – 2017. – Vol. 129 (9–10). – P. 317–328.
Cinacalcet and achievement of the NKF/KKDOQITM recommended target values for bone and mineral metabolism in reallworld clinical practice – the ECHO observational study / P. Urena, S. H. Jacobson, E. Zitt [et al.] // Nephrol. Dial. Transplant. – 2009. – Vol. 24. – P. 2852–2859.
Cinacalcet treatment for secondary hyperparathyroidism in dialysis patients: an observational study in routine clinical practice / J. Bover, R. Perez, M. Molina [et al.] // Nephron. Clin. Pract. – 2011. – Vol. 118. – P. 109–121.